Cytek Biosciences, Inc. (CTKB) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -2.74M | -771K | -3.9M | 108K | -125K | 2M | 13.22M | 6.2M | 3.96M | 9.51M | -4.24M | -2.85M |
| Operating CF Margin % | -6.2% | -1.24% | -7.45% | 0.24% | -0.3% | 3.47% | 25.67% | 13.31% | 8.82% | 16.33% | -8.83% | -5.74% |
| Operating CF Growth % | -2088.8% | -138.61% | -129.48% | -98.26% | -103.16% | -79.01% | 411.89% | 317.68% | 38.45% | 53.59% | 43.51% | 69.81% |
| Net Income | -18.87M | -44.08M | -5.48M | -5.58M | -11.4M | 9.64M | 940K | -10.43M | -6.17M | 5.5M | -6.46M | -4.39M |
| Depreciation & Amortization | 2.81M | 3.04M | 3.06M | 2.99M | 2.88M | 2.74M | 2.81M | 2.48M | 2.46M | 2.42M | 2.56M | 2.44M |
| Stock-Based Compensation | 4.86M | 5.53M | 5.64M | 6.79M | 6.63M | 7M | 7.05M | 7.15M | 5.64M | 5.67M | 5.76M | 5.92M |
| Deferred Taxes | -183K | 38.58M | -2.63M | -2.06M | -336K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -359K | -366K | -928K | -1.25M | -930K | -11.89M | 12.37M | -1.1M | 179K | -246K | -831K | -1.74M |
| Working Capital Changes | 9M | -3.48M | -3.56M | -785K | 3.03M | -5.5M | -9.95M | 8.11M | 1.85M | -3.84M | -5.27M | -5.09M |
| Change in Receivables | 9.64M | -6.15M | -587K | 652K | 6.45M | -9.33M | -6.25M | 5.92M | 4.24M | 263K | -6.85M | -6.8M |
| Change in Inventory | -1.63M | 2.05M | -2.22M | -3.57M | -1.5M | 2M | 3.56M | 4.43M | 4.77M | 6.33M | -1.89M | 3.03M |
| Change in Payables | 390K | -1.31M | 588K | 759K | 410K | 258K | 2.23M | -519K | 615K | -1.79M | 1.71M | -2M |
| Cash from Investing | -27.08M | -1.84M | 18.92M | -16.41M | 9.45M | -63.43M | -15.81M | 2.02M | -5.75M | 29.07M | 43.12M | 2.79M |
| Capital Expenditures | -2.17M | -1M | -657K | -1.58M | -849K | -894K | -808K | -1.05M | -567K | -1.5M | -1.33M | -1.31M |
| CapEx % of Revenue | 4.91% | 1.61% | 1.26% | 3.46% | 2.05% | 1.56% | 1.57% | 2.26% | 1.26% | 2.58% | 2.77% | 2.64% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | -471K | -76K | 0 | 0 | -1K | -1K | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -27K | 162K | 1K | -49K | 31K | 182K | -98K | -72K | -55K | -61K | -63K | -55K |
| Cash from Financing | 3.98M | -1.23M | 1.94M | -2.6M | -11.54M | -3.64M | -12.08M | -1.71M | 1.61M | -33.75M | -8.27M | 216K |
| Debt Issued (Net) | 4.2M | -1.52M | 1.95M | 1.24M | -828K | 2.65M | -135K | -142K | 1.25M | -140K | -138K | -141K |
| Equity Issued (Net) | 21K | 565K | 29K | -3.74M | -10.63M | -6.99M | -11.95M | -2.67M | 0 | -34.74M | -8.43M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 34K | 29K | -4.51M | -10.63M | -6.99M | -11.95M | -2.67M | 0 | -34.74M | -8.43M | 0 |
| Other Financing | -239K | -267K | -34K | -102K | -90K | 705K | 1K | 1.1M | 358K | 1.13M | 292K | 357K |
| Net Change in Cash | -25.19M | -2.43M | 17.81M | -19.83M | -3.45M | -63.56M | -15.62M | 8.78M | 1.51M | 4M | 32.09M | -850K |
| Free Cash Flow | -4.9M | -1.77M | -4.55M | -1.47M | -976K | 1.09M | 12.41M | 5M | 3.33M | 7.95M | -5.63M | -4.22M |
| FCF Margin % | -11.11% | -2.85% | -8.71% | -3.22% | -2.35% | 1.9% | 24.1% | 10.73% | 7.43% | 13.65% | -11.73% | -8.49% |
| FCF Growth % | -402.46% | -261.97% | -136.68% | -129.36% | -129.27% | -86.24% | 320.4% | 218.61% | 41.73% | 2006.71% | 34.62% | 60.83% |
| FCF per Share | -0.04 | -0.01 | -0.04 | -0.01 | -0.01 | 0.01 | 0.09 | 0.04 | 0.03 | 0.06 | -0.04 | -0.03 |
| FCF Conversion (FCF/Net Income) | 0.15x | 0.02x | 0.71x | -0.02x | 0.01x | 0.21x | 14.05x | -0.59x | -0.64x | 1.73x | 0.66x | 0.65x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 25K | 0 | 1.91M | 864K | 1.06M | 0 | 4.5M | 127K | 590K |